The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of all pancreatic cancers, with a 5-year survival rate of 7% and 80% of patients diagnosed with advanced or metastatic malignancies. Despite recent advances in diagnostic testing, surgical techniques, and systemic therapies, there remain limit...

Descripción completa

Detalles Bibliográficos
Autores principales: Busato, Davide, Mossenta, Monica, Dal Bo, Michele, Macor, Paolo, Toffoli, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499405/
https://www.ncbi.nlm.nih.gov/pubmed/36142190
http://dx.doi.org/10.3390/ijms231810279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499405/
https://www.ncbi.nlm.nih.gov/pubmed/36142190
http://dx.doi.org/10.3390/ijms231810279

Ejemplares similares